Oric Pharmaceuticals Surges 11.6% on Positive Drug Trial News

Analysts Remain Bullish on Biotech Stock Despite Safety Concerns

Apr. 2, 2026 at 3:50pm

Got story updates? Submit your updates here. ›

Shares of Oric Pharmaceuticals (NASDAQ:ORIC) jumped 11.6% on Thursday after the company announced positive progress in its Phase 3 clinical trial for its lead drug candidate. However, the stock's rally was tempered by concerns over potential safety issues with the higher dosage of the drug.

Why it matters

Oric Pharmaceuticals is a clinical-stage biotech company focused on developing treatments for solid tumor cancers. The success or failure of its lead drug candidate could have a significant impact on the company's future prospects and valuation.

The details

Oric Pharmaceuticals selected the 400 mg once-daily dose of its drug rinzimetostat in combination with darolutamide as the recommended Phase 3 dose for its Himalayas-1 registrational trial. This moves the program closer to a global Phase 3 start, which is expected in the first half of 2026. However, the market reaction was mixed, with some analysts expressing concerns over potential safety signals at the higher dose levels seen in the Phase 1b data.

  • Oric Pharmaceuticals selected the 400 mg once-daily dose of rinzimetostat in Q1 2026.
  • The global Phase 3 trial of rinzimetostat is expected to begin in the first half of 2026.

The players

Oric Pharmaceuticals

A clinical-stage biopharmaceutical company focused on developing treatments for solid tumor cancers.

Rinzimetostat

Oric Pharmaceuticals' lead drug candidate, an oral antagonist of the glucocorticoid receptor currently in Phase 1/2 trials.

Darolutamide

A prostate cancer drug that Oric Pharmaceuticals is evaluating in combination with rinzimetostat.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, Grocery employee

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.